RecruitingEarly Phase 1NCT06531863

Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance

A Randomized Controlled Trial to Determine the Effects of Curcumin and Epigallocatechin Gallate Supplementation on Serum Brain Derived Neurotrophic Factor and Mood Disturbance in Adults

Sponsor

Auburn University

Enrollment

64 participants

Start Date

Sep 30, 2024

Study Type

INTERVENTIONAL

Conditions

Mood disturbance

Summary

The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo. Participants will consume an 8-week supplement of both: * 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)

Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Curcumin, Epigallocatechin Gallate, and others for people with mood disturbance. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTCurcumin

1,330 mg curcumin

DIETARY_SUPPLEMENTEpigallocatechin Gallate

350 mg Epigallocatechin gallate (EGCG)

OTHERPlacebo

Placebo to be consumed after randomization.

Locations(1)

Auburn University School of Kinesiology

Auburn, Alabama, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06531863